Topical Psoralen Composition with UVB Absorbing Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PUVA treatments for conditions like psoriasis and CTCL face challenges with systemic side effects and incidental exposure to UV radiation, as existing formulations do not effectively protect the skin area and surrounding areas from UVB and UVA radiation.
Innovation Solution
A topical composition combining a photoactivable psoralen with a UVB absorbing agent in an oil-in-water emulsion or ointment form, applied to the affected area and surrounding skin to block or absorb extraneous UV radiation, minimizing exposure to harmful wavelengths during UVA therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral PUVA therapy is used to treat psoriasis and CTCL, then therapeutic efficacy is improved, but systemic side effects such as nausea and phototoxicity occur
Solution Approach 1:
The invention divides the treatment approach by using topical psoralen application combined with UVA irradiation only on affected skin areas, rather than oral administration that affects the entire body. This segmentation isolates the therapeutic action to only where needed, eliminating systemic side effects while maintaining local efficacy
Solution Approach 2:
The composition is designed to provide localized photoprotection by incorporating UVB-absorbing agents specifically in the topical formulation applied to affected areas. This creates local quality differences where treated areas receive UVA therapy while surrounding skin is protected from incidental UVB exposure
2Object-affected harmful factors
If topical PUVA treatment is used to avoid systemic side effects, then gastrointestinal side effects are reduced, but psoralen rapidly diffuses into and out of skin making treatment difficult to manage
Solution Approach 1:
The invention creates a composite topical formulation combining psoralen with UVB-absorbing agents in an ointment base. This composite structure allows the psoralen to remain localized in the skin longer while the UVB-absorbing component prevents harmful radiation from reaching deeper tissues, improving treatment manageability
Solution Approach 2:
The topical composition is applied in advance before UVA irradiation, allowing sufficient time for psoralen to penetrate and saturate the skin. The formulation is designed to maintain appropriate psoralen levels in the skin during the irradiation period, ensuring effective treatment while minimizing diffusion losses
3Area of stationary object
If broad UVA exposure is used in Bath PUVA treatment, then widespread dermatoses are treated, but incidental UVB radiation exposes affected and surrounding skin to harmful wavelengths
Solution Approach 1:
The UVB-absorbing agents in the topical formulation act as intermediary substances that selectively absorb harmful UVB radiation while allowing therapeutic UVA wavelengths to pass through and reach the skin. This intermediary layer protects the skin from UVB damage during UVA irradiation
Solution Approach 2:
The invention changes the spectral parameters of the radiation environment by introducing substances with specific absorption characteristics. The UVB-absorbing agents modify the radiation profile by filtering out UVB wavelengths (290-320 nm) while permitting UVA wavelengths (320-400 nm) to reach the treatment area
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats symptoms of psoriasis and other leukocyte-mediated diseases while reducing side effects such as nausea and phototoxicity by controlling UV exposure, providing targeted protection against UVB and UVA radiation.
Implementation Method 1
The psoralen is acts as a photosensitizer for the UVA treatment of the effected skin
Implementation Method 2
agents for absorbing or blocking extraneous radiation during phototherapy
Data Source
AI summary
Compositions containing a photoactivable agent and an agent that absorbs or blocks extraneous radiation during phototherapy are useful and used in methods to treat leukocyte mediated autoimmune diseases such as psoriasis, CTCL, and vertiligo.